SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending as investors weigh explosive potential in its compute-in-memory APU technology against persistent skepticism regarding the firm's path to commercialization and management's transparency. The community is actively debating the stock's long-term viability in the edge AI market, with heated discussions centered on recent validation reports, potential military contracts, and lingering concerns over cash burn.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is actively rallying behind the token, driven by enthusiasm for a recent podcast feature and anticipation of upcoming developments. Holders are expressing strong conviction in its deflationary tokenomics and multichain presence, frequently using the community-driven 'caw caw' call to signal ongoing momentum.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is rallying as investors react to the commercial deployment of its Dirac-3 platform and the strategic acquisition of semiconductor capabilities, signaling a transition from research to commercial hardware. The community is heavily focused on the stock's potential for a short squeeze, while highlighting the broader momentum in the photonics and quantum sectors.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as investors weigh conflicting reports of major manufacturing partnerships against concerns over the company's long-term competitive position in the semiconductor space. The stock is seeing significant volatility driven by heavy institutional volume and intense community debate over whether recent valuation gains are justified by fundamental growth or speculative market hype.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

Mistery is gaining traction as a prominent meme coin on the Cronos blockchain, with the community actively highlighting its 'rug-proof' narrative, locked developer tokens, and significant accumulation by the crypto.com/us exchange. Investors are drawing parallels to previous meme coin rallies, keeping a close watch on its correlation with CRO as they anticipate potential ecosystem growth.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is trending as investors debate the potential risks and opportunities tied to its indirect exposure to SpaceX and Anthropic through special purpose vehicles (SPVs). While many bulls are anticipating a surge driven by upcoming high-profile IPOs, others are cautious due to recent regulatory warnings regarding unauthorized SPV investment structures and the potential for share dilution.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is experiencing a parabolic rally driven by structural demand for AI memory and potential supply chain tightening from labor disputes at Samsung. While the community is debating whether this is a sustainable rerating or an overextended bubble, sentiment remains highly active with intense speculation on how far the momentum can push the price before a significant correction occurs.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is trending as investors digest recent quarterly earnings and interim Phase 1 data for its lead internal candidate, ABCL635. While some community members remain focused on long-term platform validation and the company's robust cash position, the stock is currently seeing significant volatility and intense debate between long-term holders and short-sellers over its historical price performance.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors debate the potential for a strategic acquisition or private buyout, fueled by the company's aggressive international expansion into China and persistent rumors regarding leadership changes. Community sentiment remains polarized, with many retail holders closely tracking high short interest and institutional activity while expressing frustration over the lack of a permanent CEO and the performance of recent marketing campaigns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is generating significant momentum following the release of positive interim data from its U.S. glioblastoma trial, showing high rates of local disease control and complete responses. The community remains highly engaged with this ticker, focusing on the company's progress in overcoming difficult tumor types and the anticipation of further pipeline results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tweedy Browne Co LLC Decreases Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS

Tweedy Browne Co LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with...

Ionis to host 2026 virtual Annual Meeting of Stockholders

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4...

What is HC Wainwright's Estimate for IONS Q1 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Ionis Pharmaceuticals in a report released on Thursday, April 30th. HC Wainwright analyst M. Kapoor anticipates that the company will post earni...

Kornitzer Capital Management Inc. KS Buys Shares of 29,105 Ionis Pharmaceuticals, Inc. $IONS

Kornitzer Capital Management Inc. KS bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the fourth quarter, according to its most recent filing with the Securities...

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Ionis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday...

Vanguard Group Inc. Sells 41,271 Shares of Ionis Pharmaceuticals, Inc. $IONS

Vanguard Group Inc. decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 0.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,440,459 shares of the company's...

Ionis to present at upcoming investor conferences

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America Securities 2026 Health Care...

Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Royal Bank Of Canada upped their target price on shares of Ionis Pharmaceuticals from $95.00 to $100.00 and gave the company an "outperform" rating in a report on Thursday...

IONS Q1 Earnings & Sales Beat, Stock Rises on Raised '26 View

Ionis tops Q1 estimates and lifts 2026 outlook, drives shares higher as strong drug sales and milestone revenues fuel growth.

Ionis Pharmaceuticals Q1 Earnings Call Highlights

Ionis Pharmaceuticals (NASDAQ:IONS) reported sharply higher first-quarter 2026 revenue and raised its full-year outlook, citing accelerating demand for its two commercial products and milestone-driven partner revenue. Management also outlined upcoming regulatory milestones and launch preparations fo...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Current Price	$75.38
Prev Close	$75.71
Open	$76.03
Dividend Yield	0.00%
50-Day Moving Average	$74.48
Beta	0.72
Avg. Volume	1.77M
PE Ratio	-35.86

52-Week High	$86.74
52-Week Low	$32.00
Market Capitalization	$12.51B
EPS (Annual)	-$2.38
Price to Book	25.45
Revenue Per Employee	$673,117.69

IONS
Ionis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IONS News

IONSIonis Pharmaceuticals Inc